KMB vs PMCB · P/E 19, rev $20.06B vs $8.6M cap
Kimberly-Clark Corporation (KMB) versus PharmaCyte Biotech Inc (PMCB) — a side-by-side from cached financials, not a winner call.
Kimberly-Clark Corporation (KMB) is a household & personal products company listed on US.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
Latest reported KMB revenue for 2024-12-31 was $20.06B. Net income was $2.58B. Revenue was down 1.8% from 2023-12-31 to 2024-12-31. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
KMB currently screens at market cap $32.88B and trailing P/E 19.2. PMCB currently screens at market cap $8.6M.
Not investment advice. Open the KMB and PMCB stock pages for the full models.
Not investment advice.